Should Medicare pay for Aduhelm?

In June, the FDA approved aducanumab (Aduhelm)  to treat patients with Alzheimer’s disease using the agency’s accelerated approval pathway, despite significant concerns about the evidence regarding the drug’s safety and effectiveness. The agency’s approval decision contradicted the recommendations of its own advisory committee, which  voted overwhelmingly against the evidence presented in support of the drug. Soon afterRead more …Should Medicare pay for Aduhelm? originally appeared inKevinMD.com.

Source: Kevin, M.D. - Medical Weblog - July 24, 2021 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/michael-k-gusmano-and-karen-j-maschke" rel="tag" > Michael K. Gusmano, PhD and Karen J. Maschke, PhD < /a > < /span > Tags: Policy Neurology Source Type: blogs